文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

干扰素α/β受体基因多态性影响糖皮质激素反应及ARDS与COVID-19结局

Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.
PubMed 文献 · Crit Care · 2023-03-16
一句话结论IFNAR2基因SNP rs9984273小等位基因与IFN β治疗ARDS患者更好结局相关,大等位基因在同时使用IFN β和糖皮质激素时结局差。

研究对INTEREST试验中接受静脉注射IFN β-1a(144例)或安慰剂(152例)的ARDS患者进行IFN α/β受体编码基因测序,分析遗传背景与临床结局、合并用药及促炎细胞因子水平的关系,并在肺器官培养中检测遗传背景对IFN α/β受体表达及STAT1、STAT2转录因子的影响。发现位于IFNAR2基因、对应糖皮质激素受体结合基序区域的SNP rs9984273新疾病关联:小等位基因与更高IFNAR表达、IFN γ和IL-6水平更快下降及IFN β治疗ARDS患者更好结局相关;大等位基因与不良结局相关,尤其在同时使用IFN β和糖皮质激素时。小等位基因还根据COVID-19 Host Genetics Initiative数据库与较轻COVID-19相关。作者认为该SNP在临床研究组间的分布可能解释多项ARDS研究和COVID-19中关于I型IFN信号与糖皮质激素的矛盾结果。

要点

  • INTEREST试验中IFNAR2基因SNP rs9984273小等位基因与IFN β治疗ARDS患者更高IFNAR表达、IFN γ和IL-6更快下降及更好结局相关。
  • SNP rs9984273大等位基因与不良结局相关,尤其在同时接受IFN β和糖皮质激素治疗的ARDS患者中。
  • rs9984273位于IFNAR2基因对应糖皮质激素受体结合基序区域,小等位基因与较轻COVID-19相关(COVID-19 Host Genetics Initiative数据库)。
  • 作者认为该SNP在研究组间的分布可能解释ARDS和COVID-19中I型IFN信号与糖皮质激素的矛盾结果。

适用人群与场景

  • INTEREST试验(NCT02622724,2015年11月24日)中随机接受静脉注射IFN β-1a(144例)或安慰剂(152例)的ARDS患者。

研究设计与关键结果

  • 研究类型:基于INTEREST III期试验的遗传关联分析,对患者IFN α/β受体编码基因进行测序,分析遗传背景与临床结局、合并用药及促炎细胞因子水平的关系,并在肺器官培养中检测遗传背景对IFN α/β受体表达及STAT1、STAT2转录因子的影响。
  • 发现SNP rs9984273位于IFNAR2基因对应糖皮质激素受体结合基序区域,为新疾病关联。
  • rs9984273小等位基因与更高IFNAR表达、IFN γ和IL-6水平更快下降及IFN β治疗ARDS患者更好结局相关。
  • rs9984273大等位基因与不良结局相关,尤其在同时使用IFN β和糖皮质激素治疗时。
  • 根据COVID-19 Host Genetics Initiative数据库,rs9984273小等位基因与较轻COVID-19相关。

证据类型、等级与局限

  • 证据类型:基于INTEREST随机对照试验的遗传关联分析及肺器官培养实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该SNP在临床研究组间的分布可能解释多项ARDS研究和COVID-19中关于I型IFN信号与糖皮质激素的矛盾结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of glucocorticoids has given contradictory results for treating acute respiratory distress syndrome (ARDS). The use of intravenous Interferon beta (IFN β) for the treatment of ARDS was recently tested in a phase III ARDS trial (INTEREST), in which more than half of the patients simultaneously received glucocorticoids. Trial results showed deleterious effects of glucocorticoids when administered together with IFN β, and therefore, we aimed at finding the reason behind this.

METHODS: We first sequenced the genes encoding the IFN α/β receptor of the patients, who participated in the INTEREST study (ClinicalTrials.gov Identifier: NCT02622724 , November 24, 2015) in which the patients were randomized to receive an intravenous injection of IFN β-1a (144 patients) or placebo (152 patients). Genetic background was analyzed against clinical outcome, concomitant medication, and pro-inflammatory cytokine levels. Thereafter, we tested the influence of the genetic background on IFN α/β receptor expression in lung organ cultures and whether, it has any effect on transcription factors STAT1 and STAT2 involved in IFN signaling.

RESULTS: We found a novel disease association of a SNP rs9984273, which is situated in the interferon α/β receptor subunit 2 (IFNAR2) gene in an area corresponding to a binding motif of the glucocorticoid receptor (GR). The minor allele of SNP rs9984273 associates with higher IFNAR expression, more rapid decrease of IFN γ and interleukin-6 (IL-6) levels and better outcome in IFN β treated patients with ARDS, while the major allele associates with a poor outcome especially under concomitant IFN β and glucocorticoid treatment. Moreover, the minor allele of rs9984273 associates with a less severe form of coronavirus diseases (COVID-19) according to the COVID-19 Host Genetics Initiative database.

CONCLUSIONS: The distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signaling and glucocorticoids.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Jalkanen J, Khan S, Elima K, et al. Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Crit Care. 2023. PMID: 36927455. doi:10.1186/s13054-023-04388-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。